PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-116.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-52.01%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-52.01%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-52.47%
Negative net income growth while AGEN stands at 19.48%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.48%
Negative EPS growth while AGEN is at 23.83%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.48%
Negative diluted EPS growth while AGEN is at 24.85%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.17%
Share count expansion well above AGEN's 5.86%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.17%
Diluted share count expanding well above AGEN's 7.25%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
582.93%
OCF growth above 1.5x AGEN's 17.06%. David Dodd would confirm a clear edge in underlying cash generation.
577.68%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
131.96%
5Y OCF/share CAGR above 1.5x AGEN's 42.43%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
210.81%
3Y OCF/share CAGR above 1.5x AGEN's 40.08%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
88.12%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
91.00%
5Y net income/share CAGR above 1.5x AGEN's 41.54%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
67.11%
3Y net income/share CAGR 1.25-1.5x AGEN's 50.31%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
1963.85%
10Y equity/share CAGR above 1.5x AGEN's 133.84%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-27.97%
Negative 5Y equity/share growth while AGEN is at 107.09%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
5.99%
Below 50% of AGEN's 101.07%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Asset growth above 1.5x AGEN's 3.37%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.97%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
1244.16%
Debt growth far above AGEN's 24.68%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
6.71%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
86.34%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.